Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: This paper is to offer insights for designing research utilizing Olink technology to identify biomarkers and potential therapeutic targets for disease treatment.
Experimental Design: We discusses the application of Olink technology in oncology, cardiovascular, respiratory and immune-related diseases, and Outlines the advantages and limitations of Olink technology.
Results: Olink technology simplifies the search for therapeutic targets, advances proteomics research, reveals the pathogenesis of diseases, and ultimately helps patients develop precision treatments.
Conclusions: Although proteomics technology has been rapidly developed in recent years, each method has its own disadvantages, so in the future research, more methods should be selected for combined application to verify each other.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/prca.202300233 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Brief Evaluation of Olink Reveal Proximity Extension Assay for High-Throughput Proteomics: A Case Study Using NIST SRM 1950 and Two Spike-In Protein Standards.
J Proteome Res
September 2025
Center for Proteomics and Metabolomics, Leiden University Medical Center, Postbus 9600, 2300 RC Leiden, The Netherlands.
Plasma proteomics has regained attention in recent years through advancements in mass spectrometry instrumentation and sample preparation as well as new high-throughput affinity-based technologies. Here, we evaluate the analytical performance of the new Olink Reveal platform, a proximity extension assay (PEA)-based technology quantifying 1034 proteins and covering many biological pathways, in particular immune system processes. Using spiked-in recombinant Interleukin-10 (IL-10) and vascular endothelial growth factor D (VEGF-D) in the NIST SRM 1950 plasma standard, we assessed the linearity, sensitivity, precision, and accuracy of the Olink Reveal assay.
View Article and Find Full Text PDFPlasma Protein Patterns Associated with Paliperidone Palmitate Maintenance Therapy in Schizophrenia: A Prospective Cohort Study.
CNS Drugs
August 2025
Department of Pharmacy, The Second Affiliated HospitalZhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
Unlabelled: BACKGROUND AND OBJECTIVE: Patients with schizophrenia exhibit significant interindividual variations in their response to pharmacotherapy, adverse effects, and clinical outcomes. While once-monthly paliperidone palmitate (PP1M) injections can improve treatment adherence and continuity compared with oral formulations, suboptimal therapeutic outcomes are still observed in some patients. Although the mechanisms underlying the variability in efficacy of long-acting injectables (LAIs) remain unclear, studies suggest an association with alterations in plasma protein expression.
View Article and Find Full Text PDFA plasma proteomics-based candidate biomarker panel predictive of amyotrophic lateral sclerosis.
Nat Med
August 2025
Neuromuscular Diseases Research Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Identifying a reliable biomarker for amyotrophic lateral sclerosis (ALS) is crucial for clinical practice. Here, in this cross-sectional study, we used the Olink Explore 3072 platform to investigate plasma proteomics as a biomarker tool for this neurodegenerative condition. Thirty-three proteins were differentially abundant in the plasma of patients with ALS (n = 183) versus controls (n = 309).
View Article and Find Full Text PDFMulti-omics integration predicts 17 disease incidences in the UK Biobank.
medRxiv
August 2025
Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Importance: Traditional clinical predictors for disease risks have limitations in capturing underlying disease complexity. Multi-omics technologies, such as metabolomics and proteomics, offer deeper molecular perspectives that could enhance risk prediction, but large-scale studies integrating the two omics are scarce.
Objectives: The primary objective is to systematically evaluate whether adding metabolomics and/or proteomics data to traditional clinical predictors improves risk prediction for 17 common incident diseases.
Proteomic signatures of the ε and ε genetic variants and Alzheimer's disease.
medRxiv
August 2025
Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden.
The ε4 and ε2 alleles of the Apolipoprotein E () gene confer opposite genetic risks for Alzheimer's disease (AD), but their underlying molecular mechanisms remain poorly characterized in humans. To resolve this, we systematically profiled -associated proteomic alterations across five cohorts-including the Global Neurodegeneration Proteomics Consortium (GNPC), BioFINDER-2, the Alzheimer's Disease Neuroimaging Initiative (ADNI), the Parkinson's Progression Markers Initiative (PPMI), and UK Biobank (UKB)-using SomaLogic and OLINK platforms in plasma and cerebrospinal fluid (CSF) from over 10,000 individuals. Using GNPC (plasma SomaLogic, N=4,045), we mapped a comprehensive -protein network and applied mediation modeling to classify genotype-related signals as upstream mediators, downstream consequences, or -specific changes.
View Article and Find Full Text PDF